AC
AXSM icon

Allstate Corporation’s Axsome Therapeutics AXSM Stock Holding History

Allstate Corporation’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Sell
1,408
-7,368
-84% -$1.6M ﹤0.01% 1170
2026
Q1 		$1.48M Buy
+8,776
New +$1.52M 0.02% 639

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allstate Corporation's AXSM Position: Q2 2026 in Review

Allstate Corporation reduced its Axsome Therapeutics (AXSM) stake by 84% in Q2 2026, selling an estimated $1.6M and leaving 1,408 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1170.

Allstate Corporation first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.48M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Allstate Corporation held 1,408 shares of Axsome Therapeutics worth $345K as of Q2 2026.
  • Allstate Corporation sold 7,368 Axsome Therapeutics shares in Q2 2026, an estimated $1.6M.
  • Axsome Therapeutics made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1170 holding.
  • Allstate Corporation first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Allstate Corporation's Axsome Therapeutics position peaked at $1.48M in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.